Skip to main content
. 2023 Apr 17;5(1):vdad041. doi: 10.1093/noajnl/vdad041

Figure 2.

Figure 2.

Genetic severity, activity of mTORC1 and mTORC2 pathways in archival tumors, and best clinical response in participants treated with vistusertib. Genetic severity was classified as severe (severity score = 3), moderate (severity score = 2), or tissue mosaics (severity score = 1) according to the NF2 Genetic Severity Scoring System.21